Pfizer Inc. (PFE)
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Pfizer (PFE) points to a 25.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Pfizer Has Unreasonable Whiff Of The Marlboro Man
What makes Pfizer and Altria alike? They have trouble keeping their customers. Altria's dividend yield is 7%, even as it trades at 11 times estimated earnings over the next 12 months – a 40% premium to Pfizer. Pfizer, meanwhile, continues to provide life-saving treatments, while its dealmaking at least offers hope of future breakthroughs.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold?
Investors may stay invested in PFE stock to see how its new growth drivers perform.
2 Wonderful Dividends At Bargain Basement Prices
Market pessimism creates opportunity. Pfizer and Rexford Industrial trade at historically low valuations, offering high dividend yields and strong long-term growth potential. Pfizer's diversified drug portfolio and promising oncology pipeline support its 7.1% yield and undervalued stock price. Rexford's focus on infill industrial properties in Southern California ensures steady growth. It's supported by a 5% yield and solid financials.
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (May 2025)
Shares of Pfizer ( NYSE: PFE ) fell by 2.09% over the past month, compounding the stock's year-to-date troubles that have seen a slide of 9.11%.
3 No-Brainer Ultra-High-Yield Dividend Stocks That Are Begging to Be Bought in May
Though there are countless strategies to grow your wealth on Wall Street, few have proved as successful over the long run as buying and holding high-quality dividend stocks.
Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks
Top-ranked stocks Fox (FOXA), Universal Technical Institute (UTI), Pfizer (PFE), Tenet Healthcare (THC) and Newmont (NEM) are likely to beat on the bottom line in their upcoming releases.
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs.
Pfizer's Q1 Update May Mark A Bottom In The Stock
Pfizer is facing some revenue pressures due to some higher Medicare discounts, and this has led to a small miss on revenue delivery in Q1 FY25. Pfizer is making meaningful improvements on profitability and is on track to realize a ~12.3% margin lift from 2024 until the end of 2027 from various cost saving initiatives. Stopping R&D of an obesity drug that had $10 billion annual revenue potential is a major setback and if PFE tries M&A instead, there is a risk of overpaying again.
Pfizer's CEO said the company could make 'tremendous investments' in the US if Trump's tariffs go away
Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US.
Buy Pfizer (PFE) Stock for a Rebound After Crushing Q1 EPS Expectations?
Pfizer (PFE) shares spiked 3% in Tuesday's trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations.
